Stay updated on Ramucirumab+Pembrolizumab in Recurrent Head & Neck Cancer Clinical Trial
Sign up to get notified when there's something new on the Ramucirumab+Pembrolizumab in Recurrent Head & Neck Cancer Clinical Trial page.

Latest updates to the Ramucirumab+Pembrolizumab in Recurrent Head & Neck Cancer Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedAdded Revision: v3.4.2. Removed the government funding lapse notice and the v3.4.1 revision entry.SummaryDifference0.5%

- Check20 days agoChange DetectedNotice about a lapse in government funding and NIH Clinical Center operating status was added to the site; link to opm.gov for updates. The site revision was updated from v3.4.0 to v3.4.1.SummaryDifference0.5%

- Check28 days agoChange DetectedAdded and updated administrative metadata on the study page: No FEAR Act Data, Last Update Submitted that Met QC Criteria, Last Update Posted, and Revision: v3.4.0. Removed the older labels Last Update Submitted that met QC Criteria, Last Update Posted (Estimated), No FEAR Act data, and Revision: v3.3.4.SummaryDifference0.3%

- Check42 days agoChange DetectedFooter revision updated to v3.3.4 (replacing v3.3.3); no changes to study content, eligibility criteria, locations, or outcomes were observed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check49 days agoChange DetectedThe Study Record Dates section now shows 'Last Update Posted (Estimated)' in place of 'Last Update Posted'. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check56 days agoChange DetectedUpdates to the study timeline include a primary completion date of 2026-06-30 and a study completion date of 2026-06-30, with additional updates logged on 2025-12-28 and 2025-12-30.SummaryDifference0.3%

Stay in the know with updates to Ramucirumab+Pembrolizumab in Recurrent Head & Neck Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ramucirumab+Pembrolizumab in Recurrent Head & Neck Cancer Clinical Trial page.